Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 60, Issue 10, Pages 4161-4172Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01723
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [21471019]
Ask authors/readers for more resources
We have designed and synthesized novel piperatine compounds with low lipophilicity as sigma(1) receptor ligands. 1-(4-Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine (10) possessed a low nanomolar sigma(1) receptor affinity and a high selectivity toward the vesicular acetylcholine transporter (>20004-fold), sigma(2) receptors (52-fOld), and adenosine A(2A), adrenergic alpha(2), cannabinoid CBI, dopamine D-1, D-2L, gamma-amitiobutyric acid A (GABA(A)), NMDA, melatonin MT1, MT2, and Serntonin 5-HT1 receptors. The corresponding radiotracer [F-18]10 demonstrated high brain uptake and extremely high brain-to-blood ratios in biodistribution studies in mice. Pretreatment with the selective sigma(1) receptor agonist SA4503- significantly reduced the level of accumulation of the radiotracer in the brain. No radiometabolite of [F-18]10 was observed to enter the brain. Positron emission tomography and magnetic resonance imaging confirmed suitable kinetics and a high, specific binding of [F-18]10 to sigma(1) receptors in rat brain. Ex vivo autoradiography showed a reduced level of binding of [F-18]10 in the cortex and hippocampus of the senescence-accelerated prone (SAMP8) compared to that of the senescence-accelerated resistant (SAMR1) mite, indicating the potential dysfunction of sigma(1) receptors in Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available